Biotech Values

[DewDiligence]

(UTHR)—LQDA sues FDA in federal court:

https://liquidia.com/news-releases/news-release-details/liquidia-files-litigation-challenge-regulatory-exclusivity

Liquidia Corporation…announced today that it has filed litigation in the U.S. District Court of the District of Columbia (Case No. 1:24-cv-02428) that challenges the recent decision by the United States Food and Drug Administration (FDA) to grant 3-year new clinical investigation exclusivity (NCI exclusivity) to Tyvaso DPI.

Based on the US Supreme Court’s recent reversal of the “Chevron” doctrine, LQDA has a decent probability of prevailing against the FDA in court, IMO. (Absent the “Chevron” reversal, it’s unlikely that LQDA would have taken legal action against the FDA.)

Please see #msg-174948495 for related info.